Rodent Behavioral Assay for CSF Toxicity Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for quickly and efficiently evaluating the toxicity of human cerebrospinal fluid (CSF) and determining Alzheimer's disease or measuring the medicinal effect of agents for treating it, especially with small amounts of CSF.
Innovation Solution
Administering human CSF into the cerebral ventricle of a rodent and evaluating cognitive function using behavioral pharmacological techniques, such as the Y-maze test, to assess toxicity and the efficacy of treatments for Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bioassay methods are used to measure Aβ oligomer levels in human CSF, then measurement capability is achieved, but the method requires large amounts of CSF and is not quick or efficient
Solution Approach 1:
The patent uses rodent models as copies of the human neurological system to evaluate CSF toxicity. Instead of directly analyzing human CSF with complex bioassays requiring large volumes, the method administers small amounts of human CSF to rodent subjects and observes cognitive effects, thereby copying the human pathological response in a simpler, more efficient system.
Solution Approach 2:
The patent replaces complex biochemical measurement systems with behavioral observation systems. Instead of using intricate immunoassay or bioassay mechanisms to directly measure Aβ oligomers, the method substitutes these with simpler behavioral tests (such as maze tests) that observe cognitive function changes in rodents, achieving toxicity evaluation with minimal CSF volume.
2Measurement precision
If biochemical immunoassay methods are used to measure Aβ oligomer levels, then direct measurement is possible, but the low Aβ oligomer levels in CSF make successful measurement extremely difficult
Solution Approach 1:
The patent introduces rodent subjects as intermediaries between the human CSF sample and the measurement endpoint. The rodent's neurological system acts as a biological amplifier, translating the subtle presence of Aβ oligomers in CSF into observable cognitive behavioral changes, thereby overcoming the limitation of direct detection of low-concentration oligomers.
Solution Approach 2:
The patent uses disposable rodent subjects that can be rapidly procured, tested, and replaced. Each rodent serves as a single-use biological assay unit, allowing multiple independent measurements with different CSF samples without the need for complex, expensive, and time-consuming optimization of biochemical assay conditions.
3Productivity
If established bioassay methods are used for evaluating human CSF bioactivity, then measurement capability exists, but no established method can quickly and efficiently evaluate toxicity with small amounts of CSF
Solution Approach 1:
The patent segments the toxicity evaluation process into distinct phases: (1) administration of minimal CSF volume to rodent, (2) observation period for cognitive behavioral changes, and (3) evaluation phase. This segmentation allows the use of extremely small CSF volumes (much less than required by traditional methods) while maintaining evaluation capability through the rodent model system.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6(b)
AI summary
The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.